Pregnancy-Associated Breast Cancer: What Radiologists Must Know

Dafne Soto-Trujillo¹, Lourdes N. Santos Aragón², Yuki Yoshi Kimura³

1. Radiology, Centro Medico ABC, Mexico City, MEX 2. Breast Imaging, Centro Medico ABC, Mexico City, MEX 3. Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, MEX

Corresponding author: Dafne Soto-Trujillo, dafne.soto@gmail.com

Abstract

Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy, in the first year postpartum, or during breastfeeding. Imaging techniques play a significant role in the diagnosis of PABC. It is a challenging diagnosis since physiological changes seen in pregnancy and breastfeeding may limit clinical suspicion and imaging utility. The patient's well-being and the fetus must be taken into consideration for diagnosis and treatment.

Categories: Radiology

Keywords: breast cancer, pregnancy

Introduction And Background

Epidemiology

Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy, in the first year postpartum, or during breastfeeding [1]. PABC corresponds to less than 3%-5% of all cases. However, it represents up to 20% of breast cancers in women up to 30 years [2]. The reported incidence of PABC is 15-35 per 100,000 deliveries [3]. Incidence is lower during pregnancy, with 2/3 of all cases are detected in the first six months postpartum. The patients' average age is 32-34 years, which is lower than the overall incidence of breast cancer. There is a high risk associated in patients with family history and BRCA mutations. Most patients do not have a family history of breast cancer [4].

Pathologic features

As in non-pregnant women, ductal infiltrating adenocarcinoma is the most common histological type, with a lower expression of hormone receptor (estrogen and progesterone) [5], HER-2/neu expression is unclear since studies have found negative expression during pregnancy and lactation and positive expression after delivery or cessation of lactation. It is believed to be secondary to high circulating estrogen levels during pregnancy that downregulate estrogen receptors' expression in some cell lines [6]. There is a higher incidence of poorly differentiated and inflammatory breast cancer in PABC compared to non-pregnant women [7].

Clinical manifestations

Patients present with a painless palpable mass (90%) or thickening of the skin. Lymph node involvement and inflammatory changes are expected at diagnosis. Diagnosis is usually delayed due to physiological changes related to pregnancy that overlook breast masses [4]. The average tumor size at diagnosis is 3.5 cm, and lymph node metastasis is frequent. Delay in diagnosis is due to normal breast hyperplasia in pregnancy that may mask palpable masses [7]. A delay in imaging studies and invasive procedures for diagnosis based on fear of the fetus's welfare may delay management.

Review

Imaging in pregnant women

Ultrasound

Ultrasound is the initial image modality with a reported sensitivity of up to 100% and a negative predictive value of up to 100% [8]. Since there is an increase in the gland's nodularity associated with pregnancy, any mass that persists for more than two to four weeks should raise suspicion for malignancy and must be assessed initially by this imaging method.

PABC is observed as hypoechoic masses with cystic components due to associated central necrosis. The borders are irregular and may have a posterior acoustic shadow or echogenic halos [9] (Figure 1). When circumscribed margins, oval shape, and parallel orientation are seen in a suspicious lesion, benign pathology

Received 09/02/2020
Review began 09/05/2020
Review ended 09/07/2020
Published 09/09/2020

© Copyright 2020

Soto-Trujillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Soto-Trujillo D, Santos Aragón L N, Kimura Y (September 09, 2020) Pregnancy-Associated Breast Cancer: What Radiologists Must Know. Cureus 12(9): e10343. DOI 10.7759/cureus.10343

may be suggested, and no further evaluation is necessary [10].

FIGURE 1: A 36-year-old female patient in her second trimester with a palpable mass in the left breast that presents growth in the last three months. (A) Ultrasound showing at 2:00 a hypoechoic nodule with micronodulated margins of 2.8 cm, and Doppler showing peripheral vascularity. (B) MLO projection of the left breast showing a hyperdense nodule of irregular margins (blue arrow) that causes skin retraction. A percutaneous biopsy was performed, with a triple-negative high-grade infiltrating ductal carcinoma result.

MLO, mediolateral oblique

Mammography

Bilateral mammography is recommended in patients with clinical suspicion. The sensitivity of mammography in PABC is 78%-90% (even in dense breasts). Radiation to the fetus is minimal, with an estimated dose of less than 0.03 uGy; therefore, two basic projections are encouraged [10]. Suspicion findings include nodules, masses, microcalcifications, asymmetries, distortions in the architecture, or thickening of the skin (Figure 2).

FIGURE 2: A 35-year-old patient in the immediate puerperium with a palpable nodule in the right breast. (A) MLO projection of the right

breast showing a hyperdense nodule (blue arrow) in the retroareolar region of spiculated margins that conditions skin thickening and retraction. (B) Ultrasound showing a hypoechoic nodule of 5 cm, spiculated borders in the retroareolar region. A percutaneous biopsy was performed with a moderately differentiated infiltrating ductal carcinoma result.

MLO, mediolateral oblique

Mammography is beneficial in evaluating microcalcifications, which are not seen in ultrasound evaluation and are determinant to evaluate the disease extent (multifocal multicentric and contralateral disease) [9]. Routine screening mammography must be continued in patients over 40 years three months after lactation cessation.

Magnetic Resonance

The use of MRI in patients with PABC is not used routinely recommended. It is reserved for patients in whom the cost-benefit is evident [10]. The contrasted agents are classified as type C drugs, according to the FDA. Gadolinium crosses the fetus-placental barrier and can be eliminated by the fetal kidneys. MRI is safe in breastfeeding patients since gadolinium has a minimal excretion through milk (rate of 0.0004%) [11]. According to the American College of Radiology Guidelines, breastfeeding suspension is not required [12].

Findings include masses with homogeneous, heterogeneous, or ring enhancement or non-mass lesions with segmental enhancement. A gland in lactation has a rapid physiological enhancement after the administration of contrast medium with an early plateau, associated with the increase in physiological vascularity. These findings should not be confused with malignancy (Figure 3).

FIGURE 3: A 38-year-old female patient in puerperium and lactation felt nodules on both breasts since her first trimester. Ultrasound was performed. (A) The right breast showing an isoechoic nodule with ill-defined borders with central vascularity. (B) The left breast showing a hypoechoic nodule with irregular margins and no echogenic pseudocapsule. Bilateral MRI (C and D) was performed with bilateral masses showing enhancement and restriction in the diffusion sequence (not shown). A bilateral percutaneous biopsy was performed with typical hyperplasia on the right breast and infiltrating lobular carcinoma on the left breast.

All the figures incorporated in the article have been presented at the European Congress of Radiology 2020 [13].

Conclusions

PABC should be suspected and studied in patients with a palpable mass during pregnancy, the first year of postpartum or lactation, and not settle for pregnancy changes. Early clinical suspicion and an adequate imaging approach are imperative in order to improve patient outcomes. Prognosis is worse when PABC is associated with lymph node metastasis, larger tumor size, and delayed detection.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Gestational breast cancer: epidemiology and diagnosis. (2019). Accessed: January 1, 2020: <https://www.uptodate.com/contents/gestational-breast-cancer-epidemiology-and-diagnosis>.
2. Woo JC, Yu T, Hurd TC: Breast cancer in pregnancy: a literature review. *Arch Surg*. 2003, 138:91-98. [10.1001/archsurg.138.1.91](https://doi.org/10.1001/archsurg.138.1.91)
3. Smith LH, Danielsens B, Allen ME, Cress R: Cancer associated with obstetric delivery: results of linkage with the California cancer registry. *Am J Obstet Gynecol*. 2003, 189:1128-1135. [10.1067/s0002-9378\(03\)00537-4](https://doi.org/10.1067/s0002-9378(03)00537-4)
4. Langer A, Mohallem M, Stevens D, Rouzier R, Lerebours F, Chérel P: A single-institution study of 117 pregnancy-associated breast cancers (PABC): presentation, imaging, clinicopathological data and outcome. *Diagn Interv Imaging*. 2014, 95:435-441. [10.1016/j.diii.2013.12.021](https://doi.org/10.1016/j.diii.2013.12.021)
5. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A: Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. *Cancer*. 2003, 98:1055-1060. [10.1002/cncr.11614](https://doi.org/10.1002/cncr.11614)
6. Shousha S: Breast carcinoma presenting during or shortly after pregnancy and lactation. *Arch Pathol Lab Med*. 2000, 124:1053-1060.
7. Doğer E, Çalışkan E, Mallmann P: Pregnancy associated breast cancer and pregnancy after breast cancer treatment. *J Turk Ger Gynecol Assoc*. 2011, 12:247-255. [10.5152/jtgga.2011.58](https://doi.org/10.5152/jtgga.2011.58)
8. Robbins J, Jeffries D, Roubidoux M, Helvie M: Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation. *Am J Roentgenol*. 2011, 196:716-722. [10.2214/AJR.09.3662](https://doi.org/10.2214/AJR.09.3662)
9. Vashi R, Hooley R, Butler R, Geisel J, Philpotts L: Breast imaging of the pregnant and lactating patient: physiologic changes and common benign entities. *Am J Roentgenol*. 2013, 200:329-336. [10.2214/AJR.12.9845](https://doi.org/10.2214/AJR.12.9845)
10. Ayyappan AP, Kulkarni S, Crystal P: Pregnancy-associated breast cancer: spectrum of imaging appearances. *Br J Radiol*. 2010, 83:529-534. [10.1259/bjr/17982822](https://doi.org/10.1259/bjr/17982822)
11. ACR manual on contrast media. (2020). Accessed: 01/01/2020: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf.
12. American College of Radiology. ACR Appropriateness Criteria®. Breast imaging of pregnant and lactating women. (2018). Accessed: January 1, 2020: <http://pdfs.semanticscholar.org/2f45/e02276af1f7a61103a57fcfc2b127c462784.pdf>.
13. Soto Trujillo DO, Santos LN: Pregnancy-associated breast cancer. *ECR 2020*. 2020, C-10885:[10.26044/ecr2020/C-10885](https://doi.org/10.26044/ecr2020/C-10885)